Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT07508007

Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings

Lipoprotein(a) \[Lp(a)\] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the Europe…

Germany4,500 participantsStarted 2025-11-28

Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings

All recent trials (1 shown)